GSK
GSK clinical trials: GSK plc
Every trial on ClinicalTrials.gov where GSK plc is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 5,356
- Trials linked
- 4,086
- As lead sponsor
- 1,270
- As collaborator
- 19
- Primary completions as lead sponsor, next 90 days
GSK on the catalyst calendar · GSK registry changes
- Primary completion May 3, 2027Sponsor estimatePhase 1/Phase 2NCT06702449A Study on the Safety and Immune Response of a Urinary Tract Infection (UTI) Vaccine in Adults 18-64 Years of Age and Clinical Efficacy...GlaxoSmithKline · Urinary Tract InfectionsActive, not recruitingGSKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 6, 2026ActualPhase 3NCT05263934Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With...GlaxoSmithKline · Eosinophilic Granulomatosis With PolyangiitisCompletedGSKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 30, 2026ActualPhase 3NCT04167358Linerixibat Long-term Safety, and Tolerability StudyGlaxoSmithKline · CholestasisCompletedGSKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 7, 2029Sponsor estimatePhase 2NCT07915791A Study to Assess the Efficacy and Safety of Co-administration of GSK3862995B With GSK5784283 in Adult Participants With Moderate to...GlaxoSmithKline · Pulmonary Disease, Chronic ObstructiveRecruitingGSKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 11, 2028Sponsor estimatePhase 2NCT07791043A Study to Investigate the Safety and Efficacy of Efimosfermin Alfa Compared With Placebo in Adult Participants With Alcohol-related...GlaxoSmithKline · Liver Diseases, AlcoholicRecruitingGSKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 6, 2029Sponsor estimatePhase 3NCT07782970A Study to Assess the Efficacy and Safety of GSK5784283 (Felcorekibart) in Participants With Chronic Rhinosinusitis With Nasal Polyps...GlaxoSmithKline · Nasal PolypsRecruitingGSKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 20, 2029Sponsor estimatePhase 3NCT07780669A Study to Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Moderate to Very...GlaxoSmithKline · Pulmonary Disease, Chronic ObstructiveRecruitingGSKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 16, 2030Sponsor estimatePhase 3NCT07704892A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to...GlaxoSmithKline · Metabolic Dysfunction-associated SteatohepatitisRecruitingGSKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 23, 2033Sponsor estimatePhase 3NCT07701993A Pivotal Clinical Study to Investigate the Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With...GlaxoSmithKline · Metabolic Dysfunction-associated SteatohepatitisRecruitingGSKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 2, 2029Sponsor estimatePhase 3NCT07177339eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2...GlaxoSmithKline · Pulmonary Disease, Chronic ObstructiveRecruitingGSKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 6, 2029Sponsor estimatePhase 3NCT07782957A Study to Assess the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Chronic...GlaxoSmithKline · Nasal PolypsRecruitingGSKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 13, 2030Sponsor estimatePhase 3NCT07740720A Study of the Duration of Dostarlimab in Untreated Mismatch Repair Deficient (dMMR)/ Microsatellite Instability-high (MSI-H) Locally...GlaxoSmithKline · Neoplasms, RectalNot yet recruitingGSKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 28, 2028Sponsor estimatePhase 1/Phase 2NCT07213609A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in...GlaxoSmithKline · Neoplasms, ColorectalRecruitingGSKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 16, 2029Sponsor estimatePhase 1/Phase 2NCT07947134A Study of GSK5864399 Administered Alone or in Combination With Other Anti-cancer Agents in Participants With Solid TumoursGlaxoSmithKline · Solid TumoursNot yet recruitingGSKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 24, 2031Sponsor estimatePhase 3NCT07947121A Study of Risvutatug Rezetecan in Combination With Atezolizumab in Participants With Extensive Stage Small Cell Lung Cancer...GlaxoSmithKline · Lung NeoplasmNot yet recruitingGSKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 19, 2032Sponsor estimateNo phase registeredNCT07850141Prospective Registry of Exposure to Gepotidacin (PREG)GlaxoSmithKline · Sexually Transmitted DiseasesRecruitingGSKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 14, 2032Sponsor estimatePhase 3NCT07393659A Continued Access Study for Participants Transitioning From ViiV Healthcare-sponsored or ViiV Healthcare-collaborative Parent Studies...ViiV Healthcare · HIV InfectionsRecruitingGSKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 31, 2021ActualPhase 1NCT04757974Low-dose Fostemsavir Extended Release Relative Bioavailability StudyViiV Healthcare · HIV InfectionsCompletedGSKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 4, 2029Sponsor estimatePhase 3NCT07782996A Study to Investigate the Efficacy and Safety of GSK5784283 Compared With Placebo in Participants With Uncontrolled Asthma (PERSIST...GlaxoSmithKline · AsthmaRecruitingGSKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 20, 2029Sponsor estimatePhase 3NCT07780656A Study to Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Moderate to Very...GlaxoSmithKline · Pulmonary Disease, Chronic ObstructiveRecruitingGSKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 28, 2027Sponsor estimatePhase 2NCT07202546A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)ViiV Healthcare · HIV InfectionsRecruitingGSKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 1, 2028Sponsor estimatePhase 1NCT06576271A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants, Healthy Chinese, and Japanese...GlaxoSmithKline · Systemic Lupus ErythematosusActive, not recruitingGSKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 31, 2026ActualPhase 2NCT05583344Phase 2b Study of GSK4532990 in Adults With NASHGlaxoSmithKline · Nonalcoholic Fatty Liver DiseaseCompletedGSKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 12, 2027Sponsor estimatePhase 1NCT07939594An Evaluation of the Potential for VH4011499 Drug-drug-interactionsViiV Healthcare · HIV InfectionsNot yet recruitingGSKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 5, 2027Sponsor estimatePhase 3NCT07099898A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]GlaxoSmithKline · Neoplasms, LungRecruitingGSKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 5,331 more in this window; the full list is part of TrialScanner.
Unlock with TrialScanner